Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1988-4-27
pubmed:abstractText
Increased serum levels of the amino terminal type III procollagen peptide and serum hyaluronan were demonstrated in patients with rheumatoid arthritis. In patients with active disease a significant correlation was shown between serum levels of the propeptide and hyaluronan and the clinical signs of synovitis reflecting the extent of synovial inflammation. During recovery the serum propeptide and serum hyaluronan showed a delayed decline as compared with the clinical signs of synovitis and the acute phase protein response. This probably reflects the presence of persistent subclinical chronic inflammation. Normal serum propeptide levels in rheumatoid arthritis were associated with a good prognosis without progression of erosive joint lesions. Azathioprine reduced the number of patients with progression of erosive joint lesions and caused a more marked suppression of the serum propeptide than levamisole and penicillamine.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-119643, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-3492417, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-352601, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-3613881, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-3718552, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-3782862, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-3876080, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-3906849, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-3956115, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-4056340, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-4102701, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6391849, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6445418, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6479852, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6521615, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6623009, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6623012, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6641123, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6735030, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6852623, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-6996690, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-7310140, http://linkedlifedata.com/resource/pubmed/commentcorrection/3355249-920239
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0003-4967
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
116-26
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.
pubmed:affiliation
Department of Medicine, University of Copenhagen, Hvidovre Hospital, Denmark.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't